National Diabetes Management Program in China
Official title: China Diabetes Registry - a Prospective Cohort Study of Patients With Diabetes in National Metabolic Management Centers in China
Run by Shanghai Jiao Tong University School of Medicine · NCT03811470 · Data updated 2026-11-12
This study is trying to create a nationwide database to help improve the care and understanding of diabetes in China by collecting health information and samples from patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000000 (estimated) |
| Sponsor | Shanghai Jiao Tong University School of Medicine Academic / other |
| Locations | 1 site (Multiple Locations) |
| Status | Recruiting |
| Started | May 31, 2017 |
| Main results expected | May 31, 2037 |
| Study ends | May 31, 2039 |
| Registry record updated | December 5, 2024 |
| Trial ID | NCT03811470 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this program are adults aged 18 and older with a diagnosis of diabetes.
✕Probably not a fit
Patients with significantly reduced life expectancy or active infectious diseases may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program aims to establish a nationwide prospective database for diabetes patients across multiple centers in China. It focuses on collecting clinical data and biological samples to enhance the understanding and management of various types of diabetes, including Type 1 and Type 2 diabetes. Utilizing advanced medical equipment and IoT technology, the program seeks to create an integrated online and offline care model for diabetes management. The initiative is part of a broader strategy to improve diabetes treatment and prevention in alignment with the Healthy China 2030 goals.
Why it matters
Potential benefit: If successful, this program could lead to improved diabetes management and outcomes for patients in China.
How similar studies have gone: Other studies focusing on integrated diabetes management models have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Main Inclusion Criteria: * Age ≥ 18 years old * Diagnosis of diabetes mellitus based on self-reported history of diagnosed diabetes by clinicians or in line with the current domestic diagnostic criteria for diabetes * Gender: males and females * Provide written informed consent * Satisfactory compliance Main Exclusion Criteria: * Patients with significantly reduced life expectancy (less than 5 years) * With Drug abuse * With AIDS or syphilis or infectious diseases such as viral hepatitis or tuberculosis in active phase at enrollment
Where it's running
-
National Metabolic Management center
Multiple Locations, China Recruiting
Study contacts
- Study coordinator: Guang Ning, MD,PHD
- Email: gning@sibs.ac.cn
- Phone: 008621-64370045
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Acupuncture plus vitamin B12 for diabetic heart nerve damage
This study tests whether adding acupuncture to standard care and vitamin B12 can help adults with type 2 diabetes who have damaged the nerves that control the heart.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Body composition changes after starting GLP-1 therapies in adults with obesity or type 2 diabetes
This study will follow adults with obesity and/or type 2 diabetes who are starting or adjusting a GLP-1 receptor agonist to see how their muscle and fat change over about a year.
-
Single-dose PK study of HRS-4729 in adults with and without kidney impairment
This study tests a single dose of HRS-4729 to see how the body handles it in adults with various levels of kidney function compared with healthy adults.
-
Once-daily ASC30 to See if it helps adults with obesity or overweight and Type 2 diabetes
This study tests three daily doses of ASC30 against placebo in adults who are overweight or obese and have Type 2 diabetes to see if it helps with weight loss and safety over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.